Viridian Therapeutics shares are trading higher after Wedbush maintained an Outperform rating on the stock and reiterated its price target of $42.
Portfolio Pulse from Benzinga Newsdesk
Viridian Therapeutics shares are trading higher after Wedbush maintained an Outperform rating on the stock and reiterated its price target of $42.
July 29, 2024 | 2:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Viridian Therapeutics shares are trading higher after Wedbush maintained an Outperform rating on the stock and reiterated its price target of $42.
The positive analyst rating and reiterated price target from Wedbush are likely to boost investor confidence in Viridian Therapeutics, leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100